14 completed, 10 withdrawn, 8 terminated, 1 recruiting. 22 Phase 1, 19 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 12, Withdrawn 5, Terminated 4, Unknown 1 |
| Phase 2 | 19 | Withdrawn 9, Terminated 5, Completed 4, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow devimistat: new trials by email Literature Review of devimistat trials Research Report on devimistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer CPI-613, modified Folfirinox - Pancreatic Cancer Stage IV | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2024-08-15 | 2024-08-15 | |
| Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas Devimistat, Modified FOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2023-07-01 | 2023-08-02 | |
| CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer CPI-613, modified FFX, Bevacizumab - C04.588.274.476.411.307 | Phase 1 | Withdrawn | Cornerstone Pharmaceuticals | 2023-03-30 | 2023-09-13 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2) - Pancreas Adenocarcinoma | Phase 1 | Terminated | Medical College of Wisconsin | 8 | 2022-10-31 | 2025-11-12 |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations CPI-613 - Lymphoma, Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 24 | 2018-12-31 | 2026-08-27 |
| CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer CPI 613, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 49 | 2018-12-07 | 2025-01-23 |
| Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine - Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | Cornerstone Pharmaceuticals | 200 | 2018-11-12 | 2023-02-08 |
| Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas CPI 613, mFolfirinox, Folfirinox - Pancreatic Cancer Metastatic | Phase 3 | Completed | Cornerstone Pharmaceuticals | 528 | 2018-11-09 | 2023-01-03 |
| CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer CPI-613, mFOLFIRNOX - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-08-01 | 2025-04-29 | |
| CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study - Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2018-06-01 | 2018-08-01 | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer CPI 613 in Combination With Gemcitabine and Nab-paclitaxel - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 | Unknown | Atlantic Health System | 24 | 2017-10-19 | 2018-02-19 |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome CPI-613 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2016-01-01 | 2016-12-29 | |
| 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Daunorubicin Hydrochloride - Untreated Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2015-12-01 | 2018-07-03 | |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
Showing 20 of 34. Sign in to see all of them.
Pancreatic Neoplasms (7) · Leukemia, Myeloid, Acute (6) · Neoplasms (4) · Neoplasm Metastasis (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Carcinoma, Hepatocellular (2) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Mycosis Fungoides (2) · Myelodysplastic Syndromes (2) · Recurrence (2) · Sarcoma, Myeloid (2)
Wake Forest University Health Sciences (16) · Cornerstone Pharmaceuticals (10) · University of Michigan Rogel Cancer Center (2) · Atlantic Health System (1) · David Bajor, MD (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (31) · Belgium (2) · France (2) · Germany (2) · South Korea (2) · Australia (1) · Austria (1) · Canada (1) · Israel (1) · Poland (1) · Spain (1)
Caio Rocha Lima, MD (4) · King C Lee, Ph.D. (3) · Timothy Pardee (3) · Avi Retter, M.D. (2) · Bayard Powell, MD (2) · Angela T Alistar, MD (1) · Ariela Noy, MD (1) · Bayard Powell (1) · David Bajor, MD (1) · Devalingam Mahalingam (1) · Divis K Khaira, M.D. (1) · Jimmy Ruiz (1) · Jordan Winter, MD (1) · Jorge E Cortes, MD (1) · Karen Gelmon, M.D. (1)
PMID 37678921, PMID 25165100, PMID 28495639, PMID 31512497, PMID 35354808, PMID 36479231, PMID 39088774, PMID 40454396, PMID 40674734
P30CA012197 (14), P30CA060553 (1)